Onriva Inhalation Capsule 75 mcg contains Indacaterol Maleate, a long-acting beta₂-adrenergic agonist (LABA) indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is designed for once-daily inhalation, providing sustained bronchodilation and improved respiratory function throughout the day and night.

Indacaterol Maleate works by selectively stimulating beta₂-adrenergic receptors in the smooth muscle of the airways. This stimulation leads to relaxation of bronchial smooth muscle, resulting in bronchodilation, reduced airway resistance, and improved airflow. Due to its rapid onset of action and prolonged duration, Onriva Inhalation Capsule offers effective symptom control and helps reduce breathlessness, wheezing, and chest tightness in patients with COPD.

Onriva is not intended for the relief of acute bronchospasm or for the treatment of asthma. It should be used regularly as prescribed to maintain open airways and improve lung function over time. The capsule formulation is specifically designed for inhalation using a compatible dry powder inhaler and should not be swallowed.

Following inhalation, indacaterol demonstrates minimal systemic exposure, which helps reduce the risk of systemic side effects commonly associated with beta-agonists. Its once-daily dosing regimen enhances patient adherence and convenience, making it suitable for long-term COPD management.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Onriva Inhalation Capsule 75 mcg is indicated for:

• Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)

• Relief of COPD symptoms such as breathlessness and exercise intolerance

Therapeutic Class

Long-acting beta₂-adrenergic agonist (LABA)

Pharmacology

Indacaterol Maleate is an ultra–long-acting beta₂-agonist that provides bronchodilation for at least 24 hours after a single inhaled dose. It selectively binds to beta₂-adrenergic receptors in airway smooth muscle, leading to increased cyclic AMP levels and relaxation of bronchial muscles. This results in improved lung function and reduced COPD symptoms.

Dosage and Administration

The recommended dose is one inhalation capsule (75 mcg) once daily, administered using a suitable dry powder inhaler. Capsules are for inhalation only and must not be swallowed. The dose should be taken at the same time each day. Dosage adjustments should be made only under medical supervision.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Onriva is generally well tolerated. Common side effects may include cough, nasopharyngitis, headache, throat irritation, and dizziness. Less commonly, palpitations, muscle cramps, and tremor may occur.

Precautions and Warnings

Onriva should be used with caution in patients with cardiovascular disorders, hyperthyroidism, or seizure disorders. It should not be used for acute episodes of bronchospasm or in patients with asthma unless combined with appropriate controller therapy.

Pregnancy and Lactation

The safety of indacaterol during pregnancy and lactation has not been fully established. Onriva should be used during pregnancy or breastfeeding only if the potential benefit outweighs the potential risk, as determined by a physician.

Storage Conditions

Store below 30°C in a cool and dry place, protected from moisture. Keep out of reach of children. Use capsules only with the prescribed inhaler device.